GLP-1 receptor agonist lowers CVD and renal risk: study
It's the largest primary prevention cohort enrolled to date, authors say
18th June 2019
By Clare Pain
In the longest trial yet of a glucagon-like peptide 1 (GLP-1) receptor agonist, dulaglutide has been shown to reduce major adverse events when added to usual therapies for patients with type 2 diabetes and cardiovascular disease or CVD risk factors.
Writing in the Lancet, the authors say the study shows a reduction in the number of patients developing macroalbuminuria compared with those on placebo over a mean follow-up of 5.4 years.
The REWIND study, funded by drug manufacturer Eli Lilly, included around 9900 people with type 2 diabetes,
